• Name

  Losartan potassium

• EINECS 200-287-4
• CAS No. 124750-99-8
• Article Data40
• CAS DataBase
• Density 0.986g/mLat 25°C(lit.)
• Solubility
• Melting Point ?69°C(lit.)
• Formula C₂₂H₂₂ClKN₆OK
• Boiling Point 682 °C at 760mmHg
• Molecular Weight 461.008
• Flash Point 366.3 °C
• Transport Information
• Appearance white to off-white crystalline powder
• Safety 26-36/37/39
• Risk Codes 36/37/38
• Molecular Structure
• Hazard Symbols Xi
• Synonyms Lotim;L-158086;Ocsaar;Losacor;Tenopres;Lortaan;Losaprex;Hyzaar;Niten;DuP 753;Losartan monopotassium salt;MK 954;Lorzaan;Cozaar;Llosartan;Losartanpotassium;Lorzaar;1H-Imidazole-5-methanol,2-butyl-4-chloro- 1-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]- methyl]-,monopotassium salt;2-Butyl-4-chloro-1-(2-(tetrazol-5-yl)biphenyl-4-ylmethyl)-1H-imidazole-5-methanol potassium;MK-0954;Losacar;MK 0954;potassium [2-butyl-5-chloro-3-[[4-[2-(2,3,4-triaza-1-azanidacyclopenta-2,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol;Cozaar (TN);
• PSA 89.61000
• LogP 3.89590

Synthetic route

114798-26-4

lorsartan

124750-99-8

losartan potassium

Conditions

Conditions	Yield
With potassium hydroxide In methanol; isopropyl alcohol at 20℃; for 0.5h;	90%
With potassium hydroxide In methanol for 4h; Heating / reflux;	33%
With potassium hydroxide In methanol for 1h; pH=9; Reflux;

124750-67-0

2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde

124750-99-8

losartan potassium

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1.1: sodium tetrahydroborate / methanol; N,N-dimethyl acetamide / 1 h / 5 - 20 °C 2.1: sodium azide; triethylamine hydrochloride / N,N-dimethyl acetamide / 16 h / 120 °C 2.2: 80 °C / pH 4.0 3.1: potassium hydroxide / methanol; isopropyl alcohol / 0.5 h / 20 °C View Scheme

83857-96-9

2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde

124750-99-8

losartan potassium

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1.1: potassium carbonate / N,N-dimethyl acetamide / 5 h / 20 °C 2.1: sodium tetrahydroborate / methanol; N,N-dimethyl acetamide / 1 h / 5 - 20 °C 3.1: sodium azide; triethylamine hydrochloride / N,N-dimethyl acetamide / 16 h / 120 °C 3.2: 80 °C / pH 4.0 4.1: potassium hydroxide / methanol; isopropyl alcohol / 0.5 h / 20 °C View Scheme

114772-54-2

4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile

124750-99-8

losartan potassium

Conditions

Conditions	Yield
Multi-step reaction with 4 steps 1.1: potassium carbonate / N,N-dimethyl acetamide / 5 h / 20 °C 2.1: sodium tetrahydroborate / methanol; N,N-dimethyl acetamide / 1 h / 5 - 20 °C 3.1: sodium azide; triethylamine hydrochloride / N,N-dimethyl acetamide / 16 h / 120 °C 3.2: 80 °C / pH 4.0 4.1: potassium hydroxide / methanol; isopropyl alcohol / 0.5 h / 20 °C View Scheme

114772-55-3

2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole

124750-99-8

losartan potassium

Conditions

Conditions	Yield
Multi-step reaction with 2 steps 1.1: sodium azide; triethylamine hydrochloride / N,N-dimethyl acetamide / 16 h / 120 °C 1.2: 80 °C / pH 4.0 2.1: potassium hydroxide / methanol; isopropyl alcohol / 0.5 h / 20 °C View Scheme

124750-99-8

losartan potassium

124750-92-1

2-butyl-4-chloro-1-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazole-5-carboxylic acid

Conditions

Conditions	Yield
Stage #1: losartan potassium With pyridine; potassium permanganate; tetrabutyl-ammonium chloride In water; acetone at 40 - 50℃; for 1h; Stage #2: With hydrogenchloride In water; acetone Product distribution / selectivity;	72%
Stage #1: losartan potassium With potassium hydroxide In water at 2℃; for 2h; Stage #2: With sodium periodate; ruthenium trichloride In water at 4 - 6.5℃; for 19h;

76-83-5

trityl chloride

124750-99-8

losartan potassium

124751-00-4

2-Butyl-4-chloro-1-[[2'-[1-(triphenylmethyl)-1H-tetrazol-5-yl][1,1'-biphenyl]-4-yl]methyl]-1H-imidazole-5-methanol

Conditions

Conditions	Yield
With triethylamine In dichloromethane; water

468724-95-0

cis-Pt(ethylenediamine)nitrate-chloride

124750-99-8

losartan potassium

losartan-cisULS

Conditions

Conditions	Yield
In N,N-dimethyl-formamide at 60℃; for 72h;

124750-99-8

losartan potassium

913611-27-5

2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxylic acid monohydrate

Conditions

Conditions	Yield
Multi-step reaction with 3 steps 1.1: potassium hydroxide / water / 2 h / 2 °C 1.2: 19 h / 4 - 6.5 °C 2.1: hydrogenchloride / acetic acid 3.1: water / 72 h / centrifuge tube View Scheme

Losartan potassium Specification

The Losartan potassium is one kind of white to off-white crystalline powder. The IUPAC Name of this chemical is Potassium [2-butyl-5-chloro-3-[[4-[2-(2,3,4-triaza-5-azanidacyclopenta-1,3-dien-1-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol. Besides, Losartan potassium belongs to Hypertension; Intermediates & Fine Chemicals; Pharmaceuticals; Losartan. In addition, its Classification Code is Antihypertensive; Drug / Therapeutic Agent; Human Data; Reproductive Effect. It is freely soluble in water, soluble in alcohols, and slightly soluble in common organic solvents, such as acetonitrile and methyl ethyl ketone. Losartan potassium can be used as a nonpeptide angiotensin II AT1-receptor antagonist. It is an antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.The Losartan potassium is irritating to eyes, respiratory system and skin.When you use it ,wear suitable protective clothing, gloves and eye/face protection.In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

Physical properties about Losartan potassium are:
(1)Flash Point: 366.3 °C; (2)Enthalpy of Vaporization: 105.1 kJ/mol; (3)Boiling Point: 682 °C at 760 mmHg; (4)Vapour Pressure: 1.55E-19 mmHg at 25 °C; (5)H-Bond Donor: 1; (6)H-Bond Acceptor: 6; (7)Rotatable Bond Count: 8; (8)Tautomer Count: 2; (9)Exact Mass: 460.118069; (10)MonoIsotopic Mass: 460.118069; (11)Topological Polar Surface Area: 77.7; (12)Heavy Atom Count: 31.

Structure Descriptors of Losartan potassium:
(1)Canonical SMILES: CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN=N[N-]4)CO)Cl.[K+]
(2)InChI: InChI=1S/C22H22ClN6O.K/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22;/h4-7,9-12,30H,2-3,8,13-14H2,1H3;/q-1;+1
(3)InChIKey: OXCMYAYHXIHQOA-UHFFFAOYSA-N
(4)Smiles: n1(c(nc(c1CO)Cl)CCCC)Cc1ccc(c2c(c3nnn[n-]3)cccc2)cc1.[K+]

Toxicity of Losartan potassium as follows:

dog	LD	oral	> 320mg/kg (320mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING	Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 3959, 1994.
man	TDLo	oral	10mg/kg/2W-I (10mg/kg)	BLOOD: HEMORRHAGE SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	Archives of Internal Medicine. Vol. 158, Pg. 191, 1998.
mouse	LDLo	intraperitoneal	400mg/kg (400mg/kg)	BEHAVIORAL: TREMOR LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 3959, 1994.
mouse	LDLo	oral	1gm/kg (1000mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: ATAXIA	Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 3959, 1994.
rat	LDLo	intraperitoneal	200mg/kg (200mg/kg)	BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 3959, 1994.
rat	LDLo	oral	2gm/kg (2000mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Kiso to Rinsho. Clinical Report. Vol. 28, Pg. 3959, 1994.
women	TDLo	oral	1mg/kg/1D-I (1mg/kg)	BEHAVIORAL: "HALLUCINATIONS, DISTORTED PERCEPTIONS"	Archives of Internal Medicine. Vol. 158, Pg. 2063, 1998.

 Production of Losartan potassium:
2-butyl-4-chloro-5-(hydroxymethyl) -1-[[2'-(triphenylmethyl) tetrazole -5-yl] biphenyl-4-yl] methyl] imidazole can be used to manufacture Losartan potassium under the condition of Hydrochloric acid and THF. The detailed steps are as follows: